2.42
0.13 (5.46%)
| Previous Close | 2.29 |
| Open | 2.32 |
| Volume | 536,099 |
| Avg. Volume (3M) | 1,619,874 |
| Market Cap | 221,971,568 |
| Price / Sales | 0.710 |
| Price / Book | 0.760 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| Profit Margin | -15.96% |
| Operating Margin (TTM) | -9.49% |
| Diluted EPS (TTM) | -0.700 |
| Quarterly Revenue Growth (YOY) | 10.30% |
| Total Debt/Equity (MRQ) | 2,020.06% |
| Current Ratio (MRQ) | 1.79 |
| Operating Cash Flow (TTM) | -15.64 M |
| Levered Free Cash Flow (TTM) | 5.58 M |
| Return on Assets (TTM) | -17.66% |
| Return on Equity (TTM) | -277.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Care Facilities (US) | Mixed | Bearish |
| Medical Care Facilities (Global) | Mixed | Bearish | |
| Stock | The Oncology Institute, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.5 |
| Average | -0.13 |
|
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services. |
|
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| Investment Style | Small Value |
| % Held by Insiders | 9.22% |
| % Held by Institutions | 34.63% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tiff Advisory Services, Llc | 31 Mar 2025 | 2,979,141 |
| Kent Lake Capital Llc | 30 Jun 2024 | 1,750,000 |
| Cincinnati Insurance Co | 31 Mar 2025 | 1,240,795 |
| Triatomic Management Lp | 30 Jun 2024 | 802,965 |
| 52 Weeks Range | ||
| Median | 6.00 (148.45%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B. Riley Securities | 16 Jul 2025 | 6.00 (148.45%) | Buy | 3.23 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 18 Aug 2025 | Announcement | The Oncology Institute and Doctors Healthcare Plans Partner to Elevate Oncology Care Management in South Florida |
| 13 Aug 2025 | Announcement | The Oncology Institute Reports Second Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance |
| 13 Aug 2025 | Announcement | The Oncology Institute Announces Changes to Board of Directors |
| 24 Jul 2025 | Announcement | The Oncology Institute Announces Second Quarter 2025 Earnings Release Date and Conference Call |
| 14 Jul 2025 | Announcement | The Oncology Institute Names Kristin England as Chief Administrative Officer |
| 30 Jun 2025 | Announcement | The Oncology Institute and SilverSummit Healthplan Partner to Provide Oncology Care to Over 80,000 Medicaid Members in Nevada |
| 03 Jun 2025 | Announcement | The Oncology Institute set to join the Russell 2000® and Russell 3000® Indexes |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |